Capricor Therapeutics, Inc. (NASDAQ:CAPR) Given Average Recommendation of "Buy" by Brokerages

Capricor Therapeutics, Inc. (NASDAQ:CAPR - Get Free Report) has received an average recommendation of "Buy" from the nine analysts that are presently covering the stock, Marketbeat.com reports. Eight research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. The average 12 month price target among brokers that have updated their coverage on the stock in the last year is $22.56.

CAPR has been the topic of several research analyst reports. Roth Capital lowered their price target on shares of Capricor Therapeutics from $31.00 to $12.00 and set a "buy" rating on the stock in a report on Monday. Oppenheimer decreased their price objective on Capricor Therapeutics from $43.00 to $22.00 and set an "outperform" rating on the stock in a report on Monday, June 23rd. Jones Trading dropped their price objective on shares of Capricor Therapeutics from $40.00 to $29.00 and set a "buy" rating for the company in a report on Wednesday, June 25th. Cantor Fitzgerald reissued an "overweight" rating and issued a $30.00 price target on shares of Capricor Therapeutics in a report on Wednesday, May 14th. Finally, Wall Street Zen lowered shares of Capricor Therapeutics from a "hold" rating to a "sell" rating in a report on Thursday, May 22nd.

Institutional Investors Weigh In On Capricor Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Farallon Capital Management LLC acquired a new position in shares of Capricor Therapeutics during the 4th quarter worth approximately $31,056,000. Vanguard Group Inc. grew its position in shares of Capricor Therapeutics by 44.4% during the 4th quarter. Vanguard Group Inc. now owns 2,276,784 shares of the biotechnology company's stock worth $31,420,000 after purchasing an additional 700,243 shares in the last quarter. Woodline Partners LP acquired a new position in shares of Capricor Therapeutics during the 4th quarter worth approximately $8,693,000. Octagon Capital Advisors LP acquired a new position in shares of Capricor Therapeutics during the 1st quarter worth approximately $4,270,000. Finally, Altium Capital Management LLC grew its position in shares of Capricor Therapeutics by 150.5% during the 4th quarter. Altium Capital Management LLC now owns 714,000 shares of the biotechnology company's stock worth $9,853,000 after purchasing an additional 429,000 shares in the last quarter. 21.68% of the stock is owned by institutional investors.

Capricor Therapeutics Trading Down 2.8%

NASDAQ CAPR traded down $0.21 during trading on Monday, reaching $7.18. 2,517,841 shares of the company's stock were exchanged, compared to its average volume of 2,088,353. The firm has a market capitalization of $327.98 million, a PE ratio of -5.06 and a beta of 0.82. Capricor Therapeutics has a fifty-two week low of $3.52 and a fifty-two week high of $23.40. The company's fifty day simple moving average is $10.27 and its 200-day simple moving average is $12.01.

Capricor Therapeutics (NASDAQ:CAPR - Get Free Report) last posted its quarterly earnings results on Tuesday, May 13th. The biotechnology company reported ($0.53) EPS for the quarter, missing the consensus estimate of ($0.33) by ($0.20). Capricor Therapeutics had a negative net margin of 181.71% and a negative return on equity of 62.42%. The company had revenue of $2.73 million for the quarter, compared to analysts' expectations of $3.16 million. During the same quarter in the prior year, the firm earned ($0.31) earnings per share. Equities analysts forecast that Capricor Therapeutics will post -1.21 EPS for the current fiscal year.

Capricor Therapeutics Company Profile

Capricor Therapeutics, Inc NASDAQ: CAPR is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor's lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.